* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
** In a prospective, multicenter, pilot study of 45 postmenopausal women (mean age 59 years) with Stage 0-IIIA hormone receptor−positive breast cancer receiving stable doses of adjuvant aromatase inhibitor therapy for 2 to 5 years from their diagnosis, PureVida significantly reduced C-reactive protein (CRP) levels (p<0.05). In 45 patients examined for safety, reported adverse events (AEs) included abdominal pain in 1 patient (2.2%), constipation in 5 patients (11.1%), headache in 3 patients (6.7%), and abnormal product taste (fish taste) in 14 patients (31.1%). No patients had to discontinue therapy due to AEs. This study was conducted by Oliventures. There has been substantial separate research into the potential benefits of each of the ingredients in PureVida. The PureVida trial has not been peer reviewed and more research is needed before drawing any final conclusions.